TXG 10x Genomics Inc
Price (delayed)
$21.77
Market cap
$2.62B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.02
Enterprise value
$2.33B
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin
Highlights
10x Genomics's revenue has increased by 11% YoY
10x Genomics's debt has decreased by 10% YoY and by 2.9% QoQ
The company's net income fell by 39% YoY but it rose by 9% QoQ
TXG's EPS is down by 36% year-on-year but it is up by 9% since the previous quarter
The company's quick ratio fell by 14% YoY
The company's gross margin fell by 12% YoY
Key stats
What are the main financial stats of TXG
Market
Valuations
Earnings
Shares outstanding
120.49M
Market cap
$2.62B
Enterprise value
$2.33B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.6
Price to sales (P/S)
4.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.69
Revenue
$631.73M
EBIT
-$233.21M
EBITDA
-$187.69M
Free cash flow
-$32.25M
Per share
Balance sheet
Liquidity
EPS
-$2.02
Free cash flow per share
-$0.27
Book value per share
$6.05
Revenue per share
$5.26
TBVPS
$7.57
Total assets
$929.67M
Total liabilities
$205.61M
Debt
$89.48M
Equity
$724.06M
Working capital
$468.14M
Debt to equity
0.12
Current ratio
5.22
Quick ratio
4.24
Net debt/EBITDA
1.55
Margins
Efficiency
Dividend
EBITDA margin
-29.7%
Gross margin
64.7%
Net margin
-38%
Operating margin
-40.1%
Return on assets
-25.5%
Return on equity
-32.7%
Return on invested capital
-42.6%
Return on capital employed
-28.5%
Return on sales
-36.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TXG stock price
How has the 10x Genomics stock price performed over time
Intraday
1.68%
1 week
-1.49%
1 month
0.09%
1 year
-52.87%
YTD
-61.1%
QTD
11.93%
Financial performance
How have 10x Genomics's revenue and profit performed over time
Revenue
$631.73M
Gross profit
$408.45M
Operating income
-$253.22M
Net income
-$239.78M
Gross margin
64.7%
Net margin
-38%
TXG's operating income is down by 42% year-on-year but it is up by 8% since the previous quarter
The company's net income fell by 39% YoY but it rose by 9% QoQ
10x Genomics's operating margin has decreased by 28% YoY but it has increased by 9% QoQ
10x Genomics's net margin has decreased by 25% YoY but it has increased by 10% QoQ
Growth
What is 10x Genomics's growth rate over time
Valuation
What is 10x Genomics stock price valuation
P/E
N/A
P/B
3.6
P/S
4.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.69
TXG's EPS is down by 36% year-on-year but it is up by 9% since the previous quarter
The P/B is 73% below the 5-year quarterly average of 13.2 and 43% below the last 4 quarters average of 6.2
TXG's equity is down by 9% year-on-year
The stock's price to sales (P/S) is 82% less than its 5-year quarterly average of 22.4 and 45% less than its last 4 quarters average of 7.4
10x Genomics's revenue has increased by 11% YoY
Efficiency
How efficient is 10x Genomics business performance
The return on invested capital has dropped by 73% year-on-year but it is up by 3.8% since the previous quarter
The ROE has plunged by 51% YoY but it has grown by 7% from the previous quarter
TXG's ROA is down by 49% YoY but it is up by 8% from the previous quarter
TXG's ROS is down by 26% year-on-year but it is up by 10% since the previous quarter
Dividends
What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TXG.
Financial health
How did 10x Genomics financials performed over time
The company's quick ratio fell by 14% YoY
The current ratio has contracted by 12% YoY
10x Genomics's debt is 88% lower than its equity
10x Genomics's debt has decreased by 10% YoY and by 2.9% QoQ
TXG's equity is down by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.